Read as much as you want on BostonGlobe.com, anywhere and anytime, for just 99¢.

Eli Lilly still hopeful on Alzheimer’s drug

Lilly’s Alzheimer’s drug is the second this year to fail; the other was from Pfizer and Johnson & Johnson.

Associated Press/File 2012

Lilly’s Alzheimer’s drug is the second this year to fail; the other was from Pfizer and Johnson & Johnson.

Continue reading below

Eli Lilly & Co., still hopeful about an experimental Alzheimer’s drug despite two disappointing studies, said it will do another one, probably in the third quarter of 2013 and focusing on patients with mild Alzheimer’s. This year, two clinical trials showed solanezumab did not significantly improve either the cognition or daily functioning of people with mild and moderate forms of the disease. But when those with mild Alzheimer’s were separated out, the drug was shown to significantly slow their decline in cognition.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week